[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of British Columbia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":668},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,185,0,25,[9,42,76,98,127,150,179,207,237,259,283,310,337,361,386,410,445,470,490,515,550,575,596,621,640],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053476","brain-based-prediction-of-the-dying-duration-in-humans-after-withdrawal-of-life-sustaining-therapies-to-inform-donation-after-circulatory-death-100053476",false,"NCT07698262","Brain-based Prediction of the Dying Duration in Humans After Withdrawal of Life Sustaining Therapies to Inform Donation After Circulatory Death","NeuroDCD","Inclusion Criteria:\n\n1. Age ≥ 19;\n2. Eligible for DCD\n\nExclusion Criteria:\n\nExclusion criteria will consist of :\n\n1. concurrent vasopressor doses of norepinephrine \\>0.05 mcg\u002Fkg\u002Fmin (or dose equivalent)\n2. PaO2\u002FFiO2 ratio \\\u003C150 mmHg\n3. complete high cervical spinal cord injury (C5 and above)\n4. cardiac support devices (e.g., ECMO, balloon pump, ventricular assist device)\n5. pacemaker in situ\n6. tracheostomy","ALL","19 Years",{"count":20,"type":21},102,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a new tool that uses information collected before life-sustaining treatments are withdrawn to better predict whether a patient will die within the time needed for organ donation to be possible. The tool created should help improve planning for organ donation and provide families and healthcare teams with more accurate information.",[25],"Organ Donation After Circulatory Death",[27,28],"Predicting organ donation after circulatory death","DCD","NOT_YET_RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":21},"2027-01",{"date":37,"type":21},"2030-12",{"name":39,"class":40},"University of British Columbia","OTHER",11,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100643426","virtual-reality-for-pain-and-anxiety-in-pediatric-dental-treatment-100643426","NCT07636330","Virtual Reality for Pain and Anxiety in Pediatric Dental Treatment","Effects of Immersive Virtual Reality on Pain, Anxiety, and Post-Procedural Experience in Pediatric Dental Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 6 to 12 years\n* Scheduled for a routine invasive dental procedure\n* Accompanied by a parent or legal guardian\n* Parent\u002Fguardian able to provide written informed consent\n\nExclusion Criteria:\n\n* Children with visual or hearing impairments that would prevent use of the VR headset\n* Children with a history of motion sickness\n* Children with severe cognitive or developmental delays that would prevent completion of study measures\n* Children who have previously participated in this study\n* Children requiring emergency dental treatment",true,"6 Years","12 Years",{"count":53,"type":21},80,"INTERVENTIONAL",[56],"NA","The goal of this clinical trial is to learn whether immersive virtual reality (VR) reduces pain and anxiety in children aged 6-12 years during routine dental procedures. The main questions it aims to answer are:\n\n* Does VR distraction reduce self-reported pain and anxiety during dental treatment compared to standard behaviour guidance?\n* Does VR distraction improve children's post-procedural experience and willingness to return for future dental visits?\n\nResearchers will compare children using a VR headset during dental treatment to children receiving standard behaviour guidance techniques.\n\nParticipants will:\n\n* Attend one routine dental appointment\n* Be randomly assigned to wear a VR headset or receive standard care during their procedure\n* Complete brief questionnaires about pain and anxiety before and after treatment\n* Receive a follow-up phone call 24-72 hours after the appointment",[59,60],"Dental Anxiety in Children","Pain",[62,63,64,65,66],"Distraction","Virtual reality","Pediatric Dentistry","Dental Anxiety","Procedural Pain","2026-06-30",{"date":69,"type":33},"2026-07-02",{"date":71,"type":21},"2026-06-02",{"date":73,"type":21},"2027-06-30",{"name":39,"class":40},1,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":54,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":75},"100645039","6-weeks-of-blood-flow-restriction-training-on-immune-cell-function-and-bioenergetics-100645039","NCT07676305","6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics","Impact of 6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics in Adults withT2D","Inclusion Criteria:\n\nA. Aged 19-64 years. B. Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0% C. Completing \\\u003C150 minutes of moderate-vigorous physical activity per week.\n\nExclusion Criteria:\n\nA. Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise.\n\nB. Unstable type 2 diabetes medication of the last 3 months C. Absolute contraindications to BFR (i.e., peripheral vascular disease) D. A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions E. A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) F. Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely G. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity","64 Years",{"count":85,"type":21},20,[56],"To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.",[89],"Type 2 Diabetes","RECRUITING","2026-06-23",{"date":67,"type":33},{"date":94,"type":33},"2026-02-11",{"date":96,"type":21},"2027-12-31",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":54,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100644556","implementation-of-an-encounter-based-patient-decision-aid-for-heart-failure-medications-in-heart-function-clinics-the-share-hf-pragmatic-stepped-wedge-trial-100644556","NCT07670845","Implementation of an Encounter-based Patient Decision Aid for Heart Failure Medications in Heart Function Clinics: the SHARE-HF Pragmatic, Stepped-wedge Trial","SHARE-HF","Inclusion Criteria:\n\n1. Patient in a participating HF clinic;\n2. In-person initial HF clinic visit;\n3. Age 40-85 years;\n4. Heart failure with reduced ejection fraction (HFrEF), as indicated by latest cardiac imaging demonstrating ejection fraction ≤40%.\n\nExclusion Criteria:\n\n1. Previous request to the clinic not to be contacted for research;\n2. Consent opt-out;\n3. Non-BC residents;\n4. Residents of long-term care facilities or hospice;\n5. Receiving palliative care;\n6. End-stage kidney disease on dialysis or latest estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2.","40 Years","85 Years",{"count":108,"type":21},1350,[56],"The goal of this clinical trial is to learn if a shared decision-making tool called SHARE-HF can help more people with heart failure receive guideline-recommended medications. The study includes adults with a type of heart failure called heart failure with reduced ejection fraction (HFrEF), who attend heart function clinics in British Columbia, Canada. The main question it aims to answer is:\n\n\\- Does use of SHARE-HF during clinic visits lead to more participants receiving their recommended heart failure medications after 6 months?\n\nResearchers will compare clinics using the SHARE-HF tool to clinics providing usual care to see if the tool helps more participants get their recommended medications.\n\nParticipants will use the SHARE-HF web-based tool with their clinician during regular clinic visits. The tool shows participants how their heart failure may affect their health over time, explains their medication options, and helps them and their clinician make treatment decisions together.",[112],"Heart Failure With Reduced Ejection Fraction (HFrEF)",[114,115,116,117,118],"shared decision-making","decision aid","encounter-based decision aid","guideline-directed medical therapy","GDMT","2026-06-22",{"date":121,"type":33},"2026-06-26",{"date":123,"type":21},"2026-11-02",{"date":125,"type":21},"2030-10-31",{"name":39,"class":40},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":54,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":75},"100644602","neuropathic-dental-pain--dbs-100644602","NCT07671950","Neuropathic Dental Pain & DBS","Pain Alleviation for Patients Receiving Directional Deep Brain Stimulation to Treat Neuropathic Dental Pain","Inclusion Criteria:\n\n* Age 19 to 80 years.\n* Diagnosis of Atypical Odontalgia (AO) (also known as neuropathic dental pain).\n* Receiving deep brain stimulation (DBS) treatment for AO due to inadequate response to conventional therapies, including: Pharmacological therapies, and\u002For Local anesthetics, corticosteroid injections, or nerve blocks.\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Known major depression.\n* Acute psychosis.","80 Years",{"count":136,"type":21},5,[56],"This prospective observational study will evaluate pain outcomes in patients with neuropathic dental pain (Atypical Odontalgia\u002FPhantom Tooth Pain) who undergo directional deep brain stimulation (DBS). Participants will complete validated pain, disability, quality-of-life, and mood assessments before surgery and following DBS programming. Directional stimulation will be applied to different thalamic targets to determine whether specific stimulation settings are associated with greater pain relief. The study aims to characterize changes in pain and quality of life following DBS and to identify the stimulation target associated with the greatest reduction in neuropathic dental pain.",[140,141],"Dental Neuralgia","Neuropathic Dental Pain",[141,140,143],"Deep Brain Stimulation",{"date":121,"type":33},{"date":146,"type":33},"2026-01-01",{"date":148,"type":21},"2028-01-01",{"name":39,"class":40},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":54,"phases":160,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":75},"100643987","independent-and-combined-effects-of-short-term-sulforaphane-supplementation-and-exercise-on-immunometabolism-in-healthy-adults-100643987","NCT07668596","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study","EXSFN","Inclusion Criteria:\n\n* aged between 18 and 35 years\n* not a current smoker\n* physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)\n\nExclusion Criteria:\n\n* a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)\n* currently following a ketogenic diet\n* body mass index (BMI) over 30 kg\u002Fm2\n* unable to read or communicate in English\n* having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks\n* having donated more than 0.5 L of blood within the last 4 weeks\n* currently pregnant\n* have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)","35 Years",{"count":85,"type":21},[56],"The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.",[163,164,165],"Immunometabolism","Mitochondrial Function, Bioenergetics","Inflammation",[167,168,169,163,165,170],"Nutraceuticals","Exercise","Bioenergetics","High intensity interval training","2026-06-19",{"date":173,"type":33},"2026-06-25",{"date":175,"type":33},"2026-03-01",{"date":177,"type":21},"2028-06-01",{"name":39,"class":40},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":49,"sex":17,"minAge":4,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":75},"100641572","infant-rsv-immunity-study-100641572","NCT07653347","Infant RSV Immunity Study","Understanding the Impact of Early-life RSV Infections on Infant Immunity and Long-term Health","IRIS","Inclusion Criteria:\n\nBirthing parent\u002Fchild pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.\n\nExclusion Criteria:\n\nSevere pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \\\u003C 35 weeks of gestation, or with chronic medical conditions).","6 Months",{"count":189,"type":21},300,"Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\\\u003C4 months) versus late (\\>6-9 months) in infancy.",[192,193],"Respiratory Synctial Virus","Asthma Childhood",[195,196,197,198],"cohort study","Immune response","infants","season of birth","2026-06-11",{"date":201,"type":33},"2026-06-17",{"date":203,"type":33},"2026-01-15",{"date":205,"type":21},"2029-12-01",{"name":39,"class":40},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":236},"100642528","smart-discharges-for-older-children-100642528","NCT07629154","Smart Discharges for Older Children","Smart Discharges for Older Children: A Cohort Study to Develop Prognostic Algorithms for Post-discharge Readmission and Mortality Among Children Over 5 Years of Age","Inclusion Criteria:\n\n* Age between 0 and 16 years admitted to pediatric ward of hospital for proven or suspected infection\n* Provide informed consent\n* Ability to provide contact information (phone number or address) for phone or in-person follow-up\n\nExclusion Criteria:\n\n* Child lives outside of the catchment area of a study site\n* Admitted for elective procedures, trauma, or short-term observation\n* Language barriers","5 Years","16 Years",{"count":217,"type":21},4000,"This study is an observational multi-country cohort study that aims to build algorithms that can identify children between 5 and 16 years of age admitted for proven or suspected sepsis who are at risk of mortality after they are discharged in East Africa.\n\nIn low- and middle-income countries, about 5% of children discharged after hospitalization for sepsis will die in the weeks after returning home. Doctors and parents are often unaware of this period of vulnerability and are poorly equipped to identify or handle this critical situation. This project builds on past work that developed and evaluated models and the Smart Discharges program to predict, during hospitalization, an individual child's risk of recurrent illness and mortality, as well as to provide additional post-discharge support to at-risk children.\n\nParticipants will be enrolled from facilities once they are admitted, collecting clinical and social variables. They will then be followed until 6 months post-discharge to understand what happens to them after they return home. This data will be evaluated to identify which variables collected at facilities can be predictive of mortality and recurrent illness after discharge.",[220],"Sepsis",[222,223,224,225,226,227],"pediatrics","sepsis","risk-prediction","critical care","post-discharge","patient discharge","2026-06-10",{"date":230,"type":33},"2026-06-15",{"date":232,"type":33},"2024-01-02",{"date":234,"type":21},"2027-04",{"name":39,"class":40},7,{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":54,"phases":246,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":75},"100581189","rise--shine-promoting-sleep-quality-in-chronic-stroke-with-exercise-100581189","NCT06847074","Rise & Shine: Promoting Sleep Quality in Chronic Stroke With Exercise","Inclusion Criteria:\n\nWe will include community-dwelling adults who had an ischemic or hemorrhagic stroke at least one year prior to study enrolment and have poor sleep quality - defined as a sleep efficiency of \\\u003C or = 85%, with allowance for minor upward deviations on individual nights consistent with known night-to-night variability and instrument accuracy limits, and a PSQI global score of \\> 5. Individuals must also meet these inclusion criteria: 1) aged 55 years and older; 2) a baseline MMSE score of = or \\> 22\u002F30 and a MoCA score of = or \\> 19\u002F30; 3) community-dwelling; 4) able to comply with scheduled assessments, classes, and other trial procedures; 5) read, write, and speak English with acceptable visual and auditory acuity; 6) not to start or stable (i.e., = or \\> 6 months) on a fixed dose of medication that impacts sleep (i.e., anti-arrhythmics, beta blockers, selective serotonin reuptake inhibitor, etc.) during the 26-week intervention period; 7) able to walk for a minimum of six metres with rest intervals with or without assistive devices; 8) based on interview, have an activity tolerance of 60 minutes with rest intervals; 9) not participating in any regular therapy or progressive exercise (e.g., treadmill or weight-lifting); and 10) able to safely engage in exercise as indicated by the PAR-Q+63 and written confirmation by family or study physicians.\n\nExclusion Criteria:\n\nWe will exclude individuals who: 1) are diagnosed with OSA and are not using CPAP or defined as potentially having undiagnosed OSA (AHI \\> 20) as a result of study screening; 2) have restless leg syndrome; 3) are diagnosed with dementia of any type; 4) are diagnosed with another type of neurodegenerative or neurological condition (e.g., Parkinson's disease); 5) are planning to participate, or already enrolled in, a clinical drug trial or exercise trial concurrent to this study; 6) are at high risk for cardiac complications during exercise and\u002For unable to self-regulate activity or to understand recommended activity level; 7) have clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his\u002Fher physician; or 8) have aphasia as judged by an inability to communicate by phone.","55 Years",{"count":245,"type":21},62,[56],"health problems, such as heart disease, diabetes, cognitive impairment, and dementia.\n\nAfter a person suffers a stroke, they often experience difficulties in getting a good night's sleep. Approximately half of stroke survivors have insomnia, or have trouble falling and\u002For staying asleep. Poor sleep quality among stroke survivors increases the risk of recurrent stroke by 3-fold and the risk of early death by 76%. Hence, stroke survivors need strategies to promote better sleep.\n\nFortunately, evidence shows that sleep quality can be improved with exercise, even among those who struggle with insomnia. Whether exercise training can improve sleep quality in adults with chronic stroke (i.e., at least 12 months has passed since their stroke) and poor sleep quality is not known. In addition, it is unknown if improved sleep is associated with improved outcomes in those with chronic stroke.\n\nThis study will specifically evaluate the effect of twice-weekly targeted exercise training on sleep quality over a 6-month period in persons with chronic stroke and poor sleep quality. This study will also evaluate the effect of exercise on the following outcomes: 1) sleep structure; 2) fatigue; 3) daytime sleepiness; 4) mood; 5) physical function and capacity; 6) thinking abilities; 7) heart health; and 8) quality of life. Finally, this study will examine how changes in sleep quality may be related to changes in these outcomes. Our proposed research is timely as the importance of sleep to recovery, health, and wellbeing post-stroke is increasingly recognized.",[249,250],"Stroke","Poor Quality Sleep",[168],"2026-06-08",{"date":199,"type":33},{"date":255,"type":33},"2025-05-15",{"date":257,"type":21},"2028-06-30",{"name":39,"class":40},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":54,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":75},"100642951","using-breath-tests-to-study-gut-sulfur-changes-during-dietary-therapy-100642951","NCT07640659","Using Breath Tests to Study Gut Sulfur Changes During Dietary Therapy","Sulfur on the Breath: Using Breath Biomarkers to Monitor Gut Microbial Sulfur Metabolism During Elemental and Reduced Sulfur Dietary Therapy","Sulfur-UC","Inclusion Criteria:\n\n* Age 19-70 years.\n\n  =Diagnosis of mild-to-moderate ulcerative colitis, defined by a partial Mayo score (pMayo) of 2-7.\n* Evidence of active inflammation at enrollment, defined as:\n* C-reactive protein (CRP) \\> 5 mg\u002FL; or\n* Fecal calprotectin (FCP) \\> 200 µg\u002Fg.\n* Receiving stable medical therapy for ulcerative colitis for at least 8 weeks prior to enrollment.\n* No corticosteroid use at the time of recruitment.\n* Under consideration by the treating physician for treatment escalation or biologic switch due to inadequate response to current therapy.\n\nExclusion Criteria:\n\n* Partial Mayo score (pMayo) \\> 7.\n* Pregnant or breastfeeding.\n* Body mass index (BMI) \\\u003C 18 kg\u002Fm².\n* History of an eating disorder.\n* Severe psychiatric disorder.\n* Severe medical conditions, including:\n* Active cancer;\n* Significant cardiovascular disease;\n* Diabetes mellitus; or\n* Severe food allergies.\n* Known allergy or intolerance to corn, dextrose, or maltodextrin.\n* Antibiotic use within 3 months prior to enrollment.\n* Probiotic use within 3 months prior to enrollment.\n* Use of herbal anti-inflammatory supplements during the study period, including but not limited to:\n* Serrapeptidase;\n* Curcumin;\n* Boswellia; or\n* Bromelain.\n* History of major gastrointestinal surgery, including:\n* Ostomy;\n* Total colectomy; or\n* Short bowel syndrome.\n* Inability or unwillingness to comply with study procedures, including anticipated travel or other commitments that may interfere with participation.","70 Years",{"count":269,"type":21},45,[56],"This study aims to test whether a short liquid-based diet, followed by a low-sulfur eating plan, is safe, manageable, and helpful for people with mild to moderate ulcerative colitis. Investigators want to see if this approach can improve gut health, lower inflammation, and reduce symptoms. Investigators will also test breath samples as an easy, non-invasive way to track gut bacteria activity and disease changes. Investigators believe this diet plan can reduce harmful gut bacteria that produce irritating sulfur compounds, leading to better gut health and measurable improvements that can be detected through breath testing.",[273],"Ulcerative Colitis (UC)",[275],"Ulcerative colitis","2026-06-05",{"date":199,"type":33},{"date":279,"type":21},"2026-06-01",{"date":281,"type":21},"2029-12-31",{"name":39,"class":40},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":290,"minAge":158,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":54,"phases":293,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":309},"100638505","preventing-ovarian-cancer-through-opportunistic-salpingectomy-at-the-time-of-laparoscopic-cholecystectomy-100638505","NCT07625137","Preventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy","Expanding Opportunistic Bilateral Salpingectomy to Laparoscopic Cholecystectomy to Prevent Ovarian Cancer: A Feasibility and Safety Trial","Inclusion Criteria:\n\n* Individuals with fallopian tubes who are undergoing lap chole and have more than 24 hours from surgeon consult to surgery, regardless of menopausal status\n* Age of 35 years and older\n* Patient must be able to give oral and written informed consent\n* Premenopausal patients will be included but will be counseled regarding their fertility\n\nExclusion Criteria:\n\n* Less than 24 hours available from surgeon consult to surgery\n* Individuals with a desire for a future pregnancy\n* Previously had a salpingectomy or salpingo-oophorectomy","FEMALE",{"count":292,"type":21},240,[56],"This study aims to evaluate the feasibility, safety, and cost-effectiveness of opportunistic salpingectomy (OS-the removal of the fallopian tubes) at the time of laparoscopic cholecystectomy (the removal of the gallbladder) to prevent ovarian cancer. Ovarian cancer is the fifth leading cause of cancer-related mortality in females in Canada. OS can prevent the most common and lethal type of ovarian cancer, high-grade serous carcinoma (HGSC). OS during gynecologic surgery (hysterectomy or instead of tubal ligation) is safe and effective. However, rates of hysterectomies and tubal sterilization are decreasing. This research team aims to extend the prevention of ovarian cancer by expanding to offer OS during other surgeries in the abdomen, when patients are already undergoing a surgical procedure. This study will examine: 1) the feasibility of OS at the time of laparoscopic cholecystectomy; 2) the safety of OS at the time of laparoscopic cholecystectomy; 3) any health services consequences of offering OBS during laparoscopic cholecystectomy.\n\nThe hypothesis is that OS at the time of laparoscopic cholecystectomy is a feasible, safe, and cost-effective primary prevention strategy for ovarian cancer. It is also hypothesized that there will be 10-20 minutes of additional operating room time for completing OS, and that integrating the identified partners and knowledge users, as well as adding relevant knowledge users as the project progresses, will affect the rapid mobilization of our findings.",[296,297],"Salpingectomy","Laparoscopic Cholecystectomy",[296,299,300,301,297],"Ovarian Neoplasms","Primary prevention","Cholecystectomy",{"date":303,"type":33},"2026-06-04",{"date":305,"type":21},"2026-07-01",{"date":307,"type":21},"2029-03-02",{"name":39,"class":40},3,{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":54,"phases":321,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":334,"leadSponsor":336,"locationsCount":75},"100599867","evaluating-treatment-strategies-for-p53-mutant-oral-cancer-and-oral-cancer-precursors-100599867","NCT07090070","Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors","Evaluating Treatment Strategies for p53 Mutant Oral Epithelial Dysplasia and SCC Study","p53 RCT","Inclusion Criteria:\n\n* Adults age 18 or over\n* No history of head and neck radiation\n* p53-abnormal IHC patterns (surrogate marker for TP53 mutation)\n\nCohort 1:\n\n* Biopsy-confirmed mild\u002Fmoderate dysplasia\n\nCohort 2:\n\n* Biopsy-confirmed severe dysplasia or CIS\n\nCohort 3:\n\n* T1 SCC with depth of Invasion (DOI) \\\u003C4mm\n* Clinically and radiologically node-negative (confirmed by contrast-enhanced CT)\n\nExclusion Criteria:\n\n* Immunocompromised status\n* Lesions greater than 3 cm\n* Presence of Proliferative Verrucous Leukoplakia\n\nCohort 1:\n\n* Had prior treatment for oral premalignant lesions\n\nCohort 2:\n\n* Presence of invasive SCC on initial biopsy\n\nCohort 3:\n\n* Positive nodes on contrast-enhanced CT\n* DOI \\>= 4mm","18 Years",{"count":320,"type":21},636,[56],"The goal of this clinical trial is to optimize treatment strategies for patients with p53-mutant oral epithelial dysplasia (OED) and early-stage oral squamous cell carcinoma (OSCC). The main question it aims to answer is what the most optimal treatment is at each diagnostic stage. It is hypothesized that lesions with p53-abnormal low-grade dysplasia (LGD) without surgical intervention will progress to high-grade dysplasia (HGD) or SCC in 4 years. It is also predicted that a clear p53 and severe\u002FCIS excision margins in patients with p53-abnormal HGD will reduce the progression to invasive SCC, compared to clear severe\u002FCIS margins, within 4 years. Finally, it is thought that patients with p53-abnormal cT1N0 and DOI\\\u003C4mm receiving an END will have improved disease free and overall survival. This research will elucidate whether or not these hypotheses are correct.\n\nParticipants in each diagnostic cohort will be assigned to one of two different treatment options, listed below:\n\nCohort 1:\n\nA) No intervention, observation only B) Surgical excision with clear margins\n\nCohort 2:\n\nA) Surgical excision with clear severe\u002FCIS margins B) Surgical excision with clear severe\u002FCIS and p53 margins\n\nCohort 3:\n\nA) Surgical excision and elective neck dissection (END) B) Surgical excision and close follow-up, only salvage ND if development of nodal disease",[324,325],"Oral Epithelial Dysplasia (OED)","Oral Squamous Cell Carcinoma (SCC)",[327,328,329],"p53 mutant","SCC","oral epithelial dysplasia","2026-05-29",{"date":332,"type":33},"2026-06-03",{"date":279,"type":21},{"date":335,"type":21},"2032-09",{"name":39,"class":40},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":54,"phases":347,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":360},"100589592","rehabilitation-of-memory-symptoms-after-brain-concussion-100589592","NCT06956417","REhabilitation of MEMory Symptoms After BRain Concussion","REMEMBR","Inclusion Criteria:\n\n1. Age 18-59\n2. Concussion diagnosis confirmed with structured interview based on American Congress of Rehabilitation Medicine diagnostic criteria\n3. Concussion occurred between 6 and 36 months before enrollment\n4. Ongoing memory concerns\n5. Fluent in English\n6. Stable access to a computer, tablet, or smartphone with internet capability\n\nExclusion Criteria:\n\n1. Fail performance validity testing\n2. Comorbid psychiatric or neurological disorder or is taking a medication that could fully account for their memory symptoms","59 Years",{"count":346,"type":21},184,[56],"Persistent memory symptoms after concussion are common, and likely perpetuated by unhelpful illness beliefs and coping behaviors. Results from a pilot study suggested that traditional cognitive rehabilitation and a novel cognitive-behavioral therapy (CBT) protocol were both associated with improvements in subjective memory functioning. The present study will more definitively compare the effectiveness of these interventions for improving subjective memory functioning after concussion.",[350,351],"Concussion, Brain","Mild Traumatic Brain Injury",[353],"Functional cognitive disorder",{"date":71,"type":33},{"date":356,"type":33},"2025-07-02",{"date":358,"type":21},"2029-04-30",{"name":39,"class":40},8,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":54,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":75},"100535387","a-multi-centre-study-of-shoe-worn-insoles-and-knee-osteoarthritis-100535387","NCT06251167","A Multi-centre Study of Shoe-worn Insoles and Knee Osteoarthritis","A Multi-centre Feasibility Study Assessing Shoe-worn Insoles to Improve Clinical and Biomechanical Features of Knee Osteoarthritis","MULTIWEDGE","Inclusion Criteria:\n\n* medial tibiofemoral OA defined as definitive osteophytes and joint space narrowing in the medial compartment, as confirmed with radiographs\n* history of knee pain longer than 6 months\n* average self-reported knee pain of at least 3 out of 10 (using an 11-point numerical rating scale with terminal descriptors of 0 = \"no pain\" and 10 = \"worst pain imaginable\") over the 6 months prior to baseline testing\n* pain in the same foot\u002Ffeet as the painful knee(s)\n* ability to communicate in English\n* show an immediate biomechanical response to the insoles. This final eligibility criterion will be determined from an in-person biomechanical assessment after participants have passed all previous eligibility screening.\n\nExclusion Criteria:\n\n* radiographic evidence of more lateral tibiofemoral OA than medial\n* knee surgery or intra-articular injection within the previous 6 months\n* current or recent (within 6 months) corticosteroid use for any reason\n* presence of a systemic arthritic condition\n* history of knee joint replacement or tibial osteotomy\n* any other condition affecting lower limb function\n* current usage of shoe-worn insoles, or planning to acquire footwear modifications in the next 6 months\n* any previous experience with insoles that resulted in increased lower limb pain or a self- or clinician-initiated termination of use.","50 Years",{"count":371,"type":21},31,[56],"Shoe-worn insoles (also known as orthotics) can provide symptomatic relief for people with knee osteoarthritis. However, given they act at the feet, and given that many people with knee osteoarthritis also report foot pain, it is important to assess the effects of these devices at both joints. We will conduct a multi-centre randomized pilot trial to determine feasibility and preliminary efficacy.",[375],"Knee Osteoarthritis",[375,377,378,379],"Orthotics","Foot pain","Biomechanics",{"date":279,"type":33},{"date":382,"type":33},"2024-03-04",{"date":384,"type":21},"2027-04-10",{"name":39,"class":40},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":54,"phases":396,"briefSummary":397,"conditions":398,"keywords":401,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":75},"100472224","mandibular-reconstruction-preplanning-vipmr-100472224","NCT05429099","Mandibular Reconstruction Preplanning (ViPMR)","Virtual Preplanning of Mandibular Reconstruction (ViPMR): a Phase III Randomized Controlled Clinical Trial","ViPMR","Inclusion Criteria:\n\n* primary diagnosis requiring mandibulectomy and fibular or scapular free flap reconstructive surgery\n* are over the age of 18\n* cognitive ability and language skills that allow participation in the trial\n* provide informed consent\n\nExclusion Criteria:\n\n* severe comorbidities including metastatic disease\n* do not have a recent (within 30 days) CT scan and are unable\u002Funwilling to receive a head CT scan at the latest 6 days prior to surgery\n* prior history of head or neck cancer within last 5 years\n* prior history of head or neck radiation treatment at any time\n* pregnant of lactating women",{"count":395,"type":21},420,[56],"Virtual Surgical Planning (VSP), where 3D modeling is used to create 3D-printed surgical guides, has been shown to improve outcomes for patients who undergo mandibular reconstruction surgery, usually due to invasion of cancer from the oral cavity to the jaw. This trial will directly compare the outcomes of patients who receive VSP versus patients who receive the current standard of care, which is Free-Hand Surgery (FHS). They will be randomized into either treatment at a 1:1 ratio and bony union rates will be compared between 12-month postoperative CT scans for each treatment group. Secondary objectives include comparing other short and long-term complication rates, reconstruction accuracy, quality of life, and functional outcomes of VSP and FHS. An economic analysis of VSP will also be performed.",[399,400],"Oral Cavity Cancer","Oral Cancer",[399,400,402],"Mandibular Reconstruction","2026-05-28",{"date":279,"type":33},{"date":406,"type":33},"2022-10-15",{"date":408,"type":21},"2028-10-15",{"name":39,"class":40},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":267,"enrollmentInfo":416,"targetDuration":418,"studyType":22,"phases":4,"briefSummary":419,"conditions":420,"keywords":429,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":444},"100488290","nerve-transfer-surgery-to-restore-upper-limb-function-after-cervical-spinal-cord-injury-100488290","NCT05638191","Nerve Transfer Surgery to Restore Upper-limb Function After Cervical Spinal Cord Injury","Inclusion Criteria:\n\n* Traumatic, motor-complete cervical SCI (AIS A or B)\n* Male or female, ages 18-70\n* Consent and plan to undergo nerve transfer to restore grasp function in at least one limb\n* Motor grade 4-5 at C5\n* Motor grade 0-1 at C8\u002FT1\n* Injury duration within 6 months at the time of surgery\n* English-speaking and cognitively intact\n* Able to provide informed written consent\n* Able to attend and comply with the testing protocols\n\nExclusion Criteria:\n\n* Inability or unwillingness to participate in post-operative rehabilitation (in person or virtual)\n* Secondary complication of SCI (e.g., intractable neuropathic pain, edema, contracture) or major medical comorbidity (e.g., traumatic brain injury) that would independently influence response to surgery or ability to participate in rehabilitation",{"count":417,"type":21},40,"2 Years","The goal of this prospective, open-label cohort study is to assess functional outcomes in individuals with cervical spinal cord injury who have undergone nerve transfer surgery to restore upper limb function. The main questions it aims to answer are:\n\n* Does nerve transfer improve hand function in individuals with cervical spinal cord injury?\n* What factors are associated with functional improvement following nerve transfer? Researchers will compare functional outcomes at 24 months post-surgery to 1) baseline outcomes and 2) individuals with cervical spinal cord injury who did not undergo nerve transfer.\n\nParticipants who have received nerve transfer surgery as part of their regular medical care will complete functional hand tests, electrodiagnostic assessments, and questionnaires on independence and mood every 3 months for 24 months after surgery.",[421,422,423,424,425,426,427,428],"Spinal Cord Injury","Spinal Cord Injury at C5-C7 Level","SCI - Spinal Cord Injury","Upper Extremity Paralysis","Upper Extremity Dysfunction","Tetraplegia","Upper Extremity Paresis","Cervical Spinal Cord Injury",[430,431,432,433,434,435,436],"spinal cord injury","upper extremity nerve transfer","nerve transfer","SCI","nerve reconstruction","quadriplegia","paresis","2026-05-27",{"date":330,"type":33},{"date":440,"type":33},"2021-06-03",{"date":442,"type":21},"2028-01",{"name":39,"class":40},4,{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":49,"sex":17,"minAge":452,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":54,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":75},"100539413","end-tidal-carbon-dioxide-concentration-and-depth-of-anesthesia-in-children-100539413","NCT06303518","End Tidal Carbon Dioxide Concentration and Depth of Anesthesia in Children","Effects of End Tidal Carbon Dioxide Concentration on Depth of Anesthesia in Children Undergoing Total Intravenous Anesthesia","Inclusion Criteria:\n\n* Children aged 3 - 11 years undergoing non- or minimally-stimulating elective procedures, defined as anesthesia without skin incision or painful manipulation (e.g., non-invasive imaging, auditory brainstem response testing), middle ear surgery, surgery with effective local or regional anesthesia before surgical incision (e.g dental procedures with local anesthetic infiltration, urology with regional block).\n* American Society of Anesthesiologists (ASA) physical status I and II\n* TIVA technique appropriate throughout induction and maintenance of anesthesia\n* Controlled ventilation via endotracheal tube\n* Anticipated surgical time ≥ 90 minutes: to allow time for anesthetic induction and subsequent testing and washout periods at all three EtCO2 levels.\n\nExclusion Criteria:\n\n* Need for inhalational induction of anesthesia\n* Sedative premedication\n* Use of ketamine intraoperatively\n* Unable to place BIS electrodes due to surgical site or other contraindications (e.g., MRI)\n* Allergy to study drugs (propofol, remifentanil, lidocaine)\n* Depression of conscious level for any reason\n* BMI \\\u003C5th or \\>95th centile for age\n* History of obstructive or central sleep apnea\n* Known or suspected raised intracranial pressure\n* Recent or historical traumatic brain injury","3 Years","11 Years",{"count":455,"type":21},100,[56],"Carbon Dioxide (CO2) is a by-product of metabolism and is removed from the body when we breathe out. High levels of CO2 can affect the nervous system and cause us to be sleepy or sedated. Research suggests that high levels of CO2 may benefit patients who are asleep under anesthesia, such as by reducing infection rates, nausea, or recovery from anesthesia . CO2 may also reduce pain signals or the medication required to keep patients asleep during anesthesia; this has not been researched in children.\n\nDuring general anesthesia, anesthesiologists keep patients asleep with anesthetic gases or by giving medications into a vein. These drugs can depress breathing; therefore, an anesthesiologist will control breathing (ventilation) with an artificial airway such as an endotracheal tube. Changes in ventilation can alter the amount of CO2 removed from the body. The anesthesiologist may also monitor a patient's level of consciousness using a 'Depth of Anesthesia Monitor' such as the Bispectral Index (BIS), which analyzes a patient's brain activity and generates a number to tell the anesthesiologist how asleep they are.\n\nThe investigator's study will test if different levels of CO2 during intravenous anesthesia are linked with different levels of sedation or sleepiness in children, as measured by BIS. If so, this could reduce the amount of anesthetic medication the child receives. Other benefits may be decreased medication costs, fewer side effects, and a positive environmental impact by using less disposable anesthesia equipment.",[459,460,461],"Anesthesia","Hypercapnia","Hypocapnia","2026-05-20",{"date":464,"type":33},"2026-05-22",{"date":466,"type":33},"2024-06-25",{"date":468,"type":21},"2026-12",{"name":39,"class":40},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":54,"phases":479,"briefSummary":480,"conditions":481,"keywords":482,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":487,"leadSponsor":489,"locationsCount":75},"100638392","split-belt-gait-retraining-in-subacute-stroke-100638392","NCT07601633","Split-Belt Gait Retraining in Subacute Stroke","Physiotherapist-Led Split-Belt Treadmill Gait Retraining for Individuals With Subacute Stroke: A Randomized Controlled Trial","Inclusion Criteria:\n\n* unilateral stroke resulting in hemiparesis\n* less than 9 months post-stroke\n* ability to walk ten metres with or without walking aids\n* ability to stand without support for five minutes\n* English speaking\n\nExclusion Criteria:\n\n* medically unfit to participate e.g. cardiac or respiratory disease limiting ability to perform walking tasks\n* neuromuscular impairment, other than stroke, limiting mobility, e.g. ankle sprain, joint disease such as severe arthritis\n* cognitive\u002Fcommunication impairment impacting ability to follow instructions\n* diagnosis of clinical depression or anxiety disorders requiring medication",{"count":478,"type":21},30,[56],"Stroke is a leading cause of long-term disability in adults. Although many individuals regain independent walking ability following stroke, nearly 50% experience persistent gait impairments characterized by asymmetrical walking patterns, slower walking speed, impaired balance, and increased fall risk. These persistent mobility limitations highlight the continued need for innovative rehabilitation strategies that improve gait function during stroke recovery. Split-belt treadmill walking (SBTW), in which each leg walks at a different belt speed, has demonstrated potential to improve step length symmetry in individuals with chronic stroke. However, the effects of SBTW during the subacute stage of stroke recovery, within the first 9 months post-stroke when neuroplasticity may be heightened, remain largely unknown. In addition, previous SBTW studies have not integrated active physiotherapist-led gait retraining into the intervention, despite physiotherapist-led gait rehabilitation representing standard clinical care following stroke. The purpose of this randomized controlled trial is to compare physiotherapist-led gait retraining using a traditional treadmill training protocol to physiotherapist-led gait retraining integrated with a split-belt treadmill training protocol during the first 9 months post-stroke. The study aims to examine the effectiveness of the use of split-belt treadmill training to augment physiotherapist-led gait retraining to improve between-leg gait symmetry and overground walking speed.",[249],[483],"split-belt walking","2026-05-15",{"date":464,"type":33},{"date":279,"type":21},{"date":488,"type":21},"2029-07-01",{"name":39,"class":40},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":290,"minAge":18,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":498,"conditions":499,"keywords":503,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":75},"100636126","predictive-value-of-early-peritraumatic-distress-screening-for-childbirth-ptsd-following-unplanned-cesarean-delivery-100636126","NCT07561632","Predictive Value of Early Peritraumatic Distress Screening for Childbirth-PTSD Following Unplanned Cesarean Delivery","PREDICT","Inclusion Criteria:\n\n* Age ≥19 years\n* Underwent unplanned cesarean delivery\n* Able to provide informed consent\n* Able to read and understand English questionnaires\n\nExclusion Criteria:\n\n* Fetal or neonatal demise\n* Unable to complete study questionnaires or provide informed consent",{"count":395,"type":21},"The goal of this observational study is to learn whether early postpartum screening tools can predict the development of childbirth-related post-traumatic stress symptoms in individuals who undergo unplanned cesarean delivery.\n\nThe main questions it aims to answer are:\n\n* Do scores on the Peritraumatic Distress Inventory (PDI) collected 24-48 hours after delivery predict childbirth-related PTSD symptoms at 6 weeks postpartum?\n* Do scores on the City Birth Trauma Scale - Short Form (CityBiTS-SF) collected 24-48 hours after delivery predict childbirth-related PTSD symptoms at 6 weeks postpartum?\n\nParticipants will:\n\n* Complete questionnaires within 24-48 hours after delivery, including the PDI, CityBiTS-SF, and Edinburgh Postnatal Depression Scale (EPDS).\n* Complete follow-up questionnaires at 6 weeks and 3 months postpartum, including measures of PTSD symptoms (PTSD Checklist for DSM-5, PCL-5) and depressive symptoms.\n\nResearchers will evaluate whether early screening scores are associated with later symptoms of childbirth-related PTSD and postpartum depression, and will assess the feasibility and acceptability of implementing routine inpatient screening for psychological birth trauma.",[500,501,502],"Post Traumatic Stress Disorder","Post Partum Depression","Acute Stress Symptoms",[504,505,506,507],"Childbirth Related PTSD","Psychological birth trauma","Peritraumatic Distress Inventory","City Birth Trauma Scale",{"date":509,"type":33},"2026-05-19",{"date":511,"type":33},"2026-05-08",{"date":513,"type":21},"2028-04",{"name":39,"class":40},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":49,"sex":17,"minAge":369,"maxAge":134,"enrollmentInfo":523,"targetDuration":4,"studyType":54,"phases":525,"briefSummary":526,"conditions":527,"keywords":534,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":75},"100620930","the-brain-health-pro-online-risk-factor-reduction-study-to-prevent-dementia-100620930","NCT07364019","The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia","The Brain Health PRO Online Risk Factor Reduction Study for The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia","BHPROOF","Inclusion Criteria:\n\n* Completion and documentation of the electronic Informed Consent Process (from the participant)\n* Sufficient proficiency in English or French to undergo online assessments and participate in an online educational program.\n* Technical ability to participate in an online educational program and remote assessments (i.e., regularly have access to a computer or tablet with an internet connection; have access to a desktop or laptop computer with an internet connection at least once every 6 months; ability to send and receive emails; ability to complete online assessments)\n* Sufficient vision to participate in an online educational program and complete online cognitive testing\n* Ages 50-80\n* Classified as being at increased risk of dementia based on at least one of the following:\n\n  * First-degree family history of dementia\n  * Education level at or below high school (grade 12 or less)\n  * Self-Reported: Hypertension, Hypercholesterolemia, Body Mass Index \\> 30 kg\u002Fm2 (derived from NIH Metric BMI Calculator), or Physical Inactivity (active is defined as engaging in a minimum of 20- 30 min of physical activity causing sweating and breathlessness, at least 2 times a week)\n\nExclusion Criteria:\n\n* Individuals who have a clinical diagnosis of Dementia (based on self-report)\n* Individuals who are currently participating in or have participated in a past study involving BHPro",{"count":524,"type":21},700,[56],"This study will recruit participants at risk for dementia to participate in an online educational program called Brain Health PRO (BHPro). The BHPro intervention is designed to address modifiable risk factors for dementia through a 6-month, fully online, educational program conveying the best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health. Achieving lifestyle changes in a diverse Canadian population through online education would be a major achievement in dementia prevention in Canada, with widespread personal and socioeconomic benefits.\n\nEligible participants will be randomly assigned to either start Brain Health PRO immediately or in 6 months (delayed-start control group). All participants will have the opportunity to have access to BHPro for 6 months during the course of the study and will have open access to all content for 12 months following the initial 6-month intervention. Participation will last from 18-24 months depending on group assignment.",[528,529,530,531,532,533],"Dementia Prevention","Subjective Cognitive Impairment","Mild Cognitive Impairment","Cognitive Change","Lifestyle Intervention","Dementia Education",[535,536,537,538,539,540,541,542],"dementia education","at risk for dementia","lifestyle intervention","dementia reduction","dementia risk factor","dementia prevention","cognitive impairment","Alzheimer risk","2026-05-14",{"date":509,"type":33},{"date":546,"type":33},"2026-05-07",{"date":548,"type":21},"2028-12-31",{"name":39,"class":40},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":49,"sex":17,"minAge":318,"maxAge":243,"enrollmentInfo":557,"targetDuration":4,"studyType":54,"phases":559,"briefSummary":560,"conditions":561,"keywords":563,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":75},"100600884","effects-of-isocapnic-respiratory-muscle-endurance-training-in-healthy-adults-100600884","NCT07103291","Effects of Isocapnic Respiratory Muscle Endurance Training in Healthy Adults","The Effects of Isocapnic Respiratory Muscle Endurance Training on the Multidimensional Components and Neurophysiological Mechanisms of Exertional Breathlessness in Healthy Adults","Inclusion Criteria:\n\n* 18-55 years of age (inclusive)\n* Male or Female (biological sex)\n* Body mass index greater than 18 or less than 30 kg\u002Fm2\n* Normal pulmonary function: FEV1\u002FFVC \\> 0.70 and FEV1 ≥ 80%\n* Able to read and understand English\n* Regularly trains and\u002For competes at a regional, national, or international level as a road cyclist or triathlete\n* Access to a device with the capability to download the Isocapnic app (Apple IOS or Google Play\u002FAndroid) or the ability to use the Web Based application.\n\nExclusion Criteria:\n\n* Currently smoke, vape, or use cannabis, or have a history of frequent smoking, vaping or cannabis use\n* History of, or current symptoms of cardiopulmonary (i.e., lung and\u002For heart) disease (excluding controlled asthma)\n* Heart problem; a serious infection within the body; a neuromuscular (nerve to muscle) or musculoskeletal (muscle, ligament and\u002For bone) disorder; or other health problem that will be made worse with exercise testing\n* Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g. a problem with the heart or lungs, muscle or bone injury, a serious infection)\n* Currently pregnant\n* Required to read and understand English due to the nature of the consent form and study materials, including questionnaires and training instructions, which are only available in English.",{"count":558,"type":21},32,[56],"Respiratory muscle training (RMT) strengthens breathing muscles and may improve exercise performance and reduce breathlessness. However, different training methods and devices create controversy in the field. Two main types of RMT exist: inspiratory muscle training (IMT) and respiratory endurance training, like voluntary isocapnic hyperpnea (VIH). While IMT is well-studied, the impact of VIH on breathlessness remains unclear. This study will use the Canadian-developed BreathWayBetter device to examine how 5 weeks of VIH affects breathing discomfort and muscle function. Findings may help personalize RMT for athletes and clinical patients, improving respiratory care and exercise tolerance.",[562],"Healthy Adults",[564,565,566,567],"Exercise physiology","Respiratory muscle training","Cycling","Competitive cyclists","2026-05-13",{"date":484,"type":33},{"date":571,"type":33},"2025-08-04",{"date":573,"type":21},"2026-08-01",{"name":39,"class":40},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":583,"conditions":584,"keywords":587,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":595,"locationsCount":75},"100460700","trikafta-exercise-study-in-cystic-fibrosis-100460700","NCT05279040","Trikafta Exercise Study in Cystic Fibrosis","Long-term Effects of Elexacaftor\u002FTezacaftor\u002FIvacaftor (Trikafta) on Exertional Symptoms, Exercise Performance, Ventilatory Responses, and Body Composition in Adults With Cystic Fibrosis","Inclusion Criteria:\n\n* Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene\n* Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit\n* Aged 19 years or older\n* Stable clinical status based on clinical judgment of the treating physician\n* Forced Expiratory Volume in 1 second (FEV1.0) \\\u003C 90% predicted\n* Body mass index greater than 16 or less than 30 kg\u002Fm\\^2\n* Currently non-smoking or a past smoking history of less than 20 pack-years\n* Able to read and understand English\n* Fully vaccinated (at least 2 doses) for Covid-19\n\nExclusion Criteria:\n\n* A disease other than CF that could importantly contribute to dyspnea or exercise limitation\n* Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians\n* Contraindications to clinical exercise testing\n* Use of supplemental oxygen or desaturation less than 85% with exercise\n* Diagnosis of pneumothorax in the past 4 weeks\n* History of organ transplantation",{"count":85,"type":21},"Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.",[585,586],"Cystic Fibrosis","Lung Diseases",[588,168,589],"Dyspnea","Trikafta",{"date":591,"type":33},"2026-05-18",{"date":593,"type":33},"2021-11-10",{"date":35,"type":21},{"name":39,"class":40},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":54,"phases":605,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":620},"100385533","effects-of-drinking-beetroot-juice-on-exercise-performance-in-patients-with-fibrotic-interstitial-lung-disease-100385533","NCT04299945","Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease","The Effects of Dietary Nitrate Supplementation on Exercise Tolerance in Patients With Fibrotic Interstitial Lung Disease","Inclusion Criteria:\n\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Oxygen saturation ≥92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nExclusion Criteria:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) (see Table 4 from ERS\u002FATS consensus statement)\n* Other significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* FVC \\\u003C50% or DLCO \\\u003C25%\n* Use of prednisone \\>10 mg\u002Fday for \\>2 weeks within 3 months of the first study visit\n* Cardiac pacemaker or any metal or electronics inside of the body",{"count":604,"type":21},15,[56],"Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD). Optimal methods of exercise training are yet to be explored in ILD. Drinking beetroot juice, which is rich in nitrate, has been shown to improve exercise performance in a variety of groups, but its effects in ILD have not been tested. The purpose of this study is to determine if drinking nitrate-rich beetroot juice can improve exercise performance compared to drinking nitrate-free beetroot juice in people with ILD.",[608],"Interstitial Lung Disease",[610,611,612,613],"ILD","Nitrates","exercise","interstitial lung disease",{"date":591,"type":33},{"date":616,"type":33},"2024-08-07",{"date":618,"type":21},"2026-12-31",{"name":39,"class":40},2,{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":49,"sex":17,"minAge":105,"maxAge":134,"enrollmentInfo":628,"targetDuration":4,"studyType":54,"phases":629,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":638,"leadSponsor":639,"locationsCount":75},"100347151","skeletal-muscle-function-in-interstitial-lung-disease-100347151","NCT03800017","Skeletal Muscle Function in Interstitial Lung Disease","Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease","Inclusion Criteria for ILD Patients:\n\n* Age 40-80 years (inclusive)\n* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses\n* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis\n* Appropriate candidate for pulmonary rehabilitation\n* 6 minute walk distance 50m or more\n* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air\n* Clinically stable for the preceding 6 weeks\n* Can fluently read and write in English\n\nInclusion Criteria for Healthy Controls:\n\n* Age 40-80 (inclusive)\n* Normal pulmonary function (80-120% predicted)\n* No lung or cardiovascular disease\n* Can fluently read and write in English\n\nExclusion Criteria for the ILD patients:\n\n* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)\n* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and\u002For oxygenation\n* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%\n* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program\n* Use of prednisone greater than 10 mg\u002Fday for more than 2 weeks within 3 months of the first study visit\n* Significant emphysema (less than 10% volume on HRCT or FEV1\u002FFVC less than 0.70)\n\nExclusion Criteria for Healthy Controls:\n\n* Currently smoking or previously smoked more than 10 pack-years\n* Any medical conditions that prevents them for exercising safely\n* Cardiac pacemaker or any metal or electronic inside the body",{"count":417,"type":21},[56],"Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.",[608,632,633,634,635],"Idiopathic Pulmonary Fibrosis","Hypersensitivity Pneumonitis","Scleroderma","Nonspecific Interstitial Pneumonia",{"date":484,"type":33},{"date":616,"type":33},{"date":618,"type":21},{"name":39,"class":40},{"id":641,"slug":642,"hasResults":12,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":646,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":4,"enrollmentInfo":648,"targetDuration":650,"studyType":22,"phases":4,"briefSummary":651,"conditions":652,"keywords":656,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":667},"100470196","st-pauls-advanced-resection-center-cohort-for-colorectal-neoplasia-sparc-c-100470196","NCT05402696","St. Paul's Advanced Resection Center Cohort for Colorectal Neoplasia (SPARC-C)","The St. Paul's Hospital Advanced Endoscopic Resection Centre Cohort for Colorectal Neoplasia (SPARC-C): A Prospective Observational Study","SPARC-C","Inclusion Criteria:\n\n* Patients ≥ 18 years of age referred for the management of an LNPCP\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Pregnant or lactating women.",{"count":649,"type":21},3500,"10 Years","The SPARC-C study is a prospective, multi-institutional observational study of patients referred for the management of large (≥ 20mm) non-pedunculated colorectal polyps (LNPCPs). Patients are managed consistent with current standards of care. Prospectively collected data includes: patient clinicodemographic details, lesion details, procedural details, and clinical outcomes.",[653,654,655],"Colon Adenoma","Colon Polyp","Colon Lesion",[657,658,659],"Colorectal neoplasia","Advanced endoscopy","Endoscopic resection","2026-05-12",{"date":484,"type":33},{"date":663,"type":33},"2022-06-27",{"date":665,"type":21},"2032-12-31",{"name":39,"class":40},6,""]